Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Imfinzi Approved for Advanced or Metastatic Biliary Tract Cancer

October 2022 Vol 8 No 5

On September 2, 2022, the FDA approved Imfinzi (durvalumab; from AstraZeneca), a PD-L1 inhibitor, for use in combination with chemotherapy, for the treatment of adults with locally advanced or metastatic (spreading) biliary tract cancer, a type of gastrointestinal (GI) cancer.

Aiwu Ruth He, MD, PhD

“This approval represents a major step forward for patients with advanced biliary tract cancer, who urgently need new, well-tolerated and effective treatment options after more than a decade of limited innovation,” said Aiwu Ruth He, MD, PhD, Associate Professor of Medicine and Leader of the GI Cancer Program, Georgetown Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC.

“The combination of durvalumab and chemotherapy should become a new standard of care in this setting, having demonstrated significantly improved survival for these patients who have historically faced a poor prognosis,” Dr. Ruth He added.

The FDA approved this new indication of Imfinzi based on results of a randomized, placebo-controlled clinical trial that included 685 patients with locally advanced, unresectable (can’t be removed by surgery) or metastatic biliary tract cancer (including 56% of patients with intrahepatic cholangiocarcinoma, 25% of patients with gallbladder cancer, and 19% with extrahepatic cholangiocarcinoma).

The patients were divided into 2 groups to receive either Imfinzi plus chemotherapy or placebo plus chemotherapy; the treatment continued until their disease progressed or they had unacceptable side effects. The average time of survival was 12.8 months in patients who received Imfinzi plus chemotherapy compared with 11.5 months in patients who received placebo plus chemotherapy. The average time without disease progression was 7.2 months with Imfinzi plus chemotherapy and 5.7 months with placebo plus chemotherapy.

Most important, 27% of the patients who received Imfinzi plus chemotherapy responded to treatment compared with only 19% of the patients who received placebo plus chemotherapy, a significant difference in terms of patients whose tumor responded to therapy.

The most common side effects reported in 20% or more of the patients receiving Imfinzi in this study were fatigue, nausea, constipation, decreased appetite, abdominal pain, rash, and pyrexia.

Recommended For You